Ischemia–Reperfusion Injury in Lung Transplantation
Lung transplantation has been established worldwide as the last treatment for end-stage respiratory failure. However, ischemia–reperfusion injury (IRI) inevitably occurs after lung transplantation. The most severe form of IRI leads to primary graft failure, which is an important cause of morbidity a...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/6/1333 |
| _version_ | 1797532354557771776 |
|---|---|
| author | Toyofumi Fengshi Chen-Yoshikawa |
| author_facet | Toyofumi Fengshi Chen-Yoshikawa |
| author_sort | Toyofumi Fengshi Chen-Yoshikawa |
| collection | DOAJ |
| description | Lung transplantation has been established worldwide as the last treatment for end-stage respiratory failure. However, ischemia–reperfusion injury (IRI) inevitably occurs after lung transplantation. The most severe form of IRI leads to primary graft failure, which is an important cause of morbidity and mortality after lung transplantation. IRI may also induce rejection, which is the main cause of mortality in recipients. Despite advances in donor management and graft preservation, most donor grafts are still unsuitable for transplantation. Although the pulmonary endothelium is the primary target site of IRI, the pathophysiology of lung IRI remains incompletely understood. It is essential to understand the mechanism of pulmonary IRI to improve the outcomes of lung transplantation. Therefore, we reviewed the state-of-the-art in the management of pulmonary IRI after lung transplantation. Recently, the ex vivo lung perfusion (EVLP) system has been clinically introduced worldwide. Various promising therapeutic strategies for the protection of the endothelium against IRI, including EVLP, inhalation therapy with therapeutic gases and substances, fibrinolytic treatment, and mesenchymal stromal cell therapy, are awaiting clinical application. We herein review the latest advances in the field of pulmonary IRI in lung transplantation. |
| first_indexed | 2024-03-10T10:57:58Z |
| format | Article |
| id | doaj.art-d6608f55a9ae4942992e7557ef678e10 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T10:57:58Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-d6608f55a9ae4942992e7557ef678e102023-11-21T21:46:49ZengMDPI AGCells2073-44092021-05-01106133310.3390/cells10061333Ischemia–Reperfusion Injury in Lung TransplantationToyofumi Fengshi Chen-Yoshikawa0Department of Thoracic Surgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, JapanLung transplantation has been established worldwide as the last treatment for end-stage respiratory failure. However, ischemia–reperfusion injury (IRI) inevitably occurs after lung transplantation. The most severe form of IRI leads to primary graft failure, which is an important cause of morbidity and mortality after lung transplantation. IRI may also induce rejection, which is the main cause of mortality in recipients. Despite advances in donor management and graft preservation, most donor grafts are still unsuitable for transplantation. Although the pulmonary endothelium is the primary target site of IRI, the pathophysiology of lung IRI remains incompletely understood. It is essential to understand the mechanism of pulmonary IRI to improve the outcomes of lung transplantation. Therefore, we reviewed the state-of-the-art in the management of pulmonary IRI after lung transplantation. Recently, the ex vivo lung perfusion (EVLP) system has been clinically introduced worldwide. Various promising therapeutic strategies for the protection of the endothelium against IRI, including EVLP, inhalation therapy with therapeutic gases and substances, fibrinolytic treatment, and mesenchymal stromal cell therapy, are awaiting clinical application. We herein review the latest advances in the field of pulmonary IRI in lung transplantation.https://www.mdpi.com/2073-4409/10/6/1333endothelial protectionex vivo lung perfusionischemia–reperfusion injurylung transplantationprimary graft dysfunction |
| spellingShingle | Toyofumi Fengshi Chen-Yoshikawa Ischemia–Reperfusion Injury in Lung Transplantation Cells endothelial protection ex vivo lung perfusion ischemia–reperfusion injury lung transplantation primary graft dysfunction |
| title | Ischemia–Reperfusion Injury in Lung Transplantation |
| title_full | Ischemia–Reperfusion Injury in Lung Transplantation |
| title_fullStr | Ischemia–Reperfusion Injury in Lung Transplantation |
| title_full_unstemmed | Ischemia–Reperfusion Injury in Lung Transplantation |
| title_short | Ischemia–Reperfusion Injury in Lung Transplantation |
| title_sort | ischemia reperfusion injury in lung transplantation |
| topic | endothelial protection ex vivo lung perfusion ischemia–reperfusion injury lung transplantation primary graft dysfunction |
| url | https://www.mdpi.com/2073-4409/10/6/1333 |
| work_keys_str_mv | AT toyofumifengshichenyoshikawa ischemiareperfusioninjuryinlungtransplantation |